vs
Side-by-side financial comparison of Gilead Sciences (GILD) and REINSURANCE GROUP OF AMERICA INC (RGA). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $6.6B, roughly 1.2× REINSURANCE GROUP OF AMERICA INC). Gilead Sciences runs the higher net margin — 27.5% vs 7.0%, a 20.6% gap on every dollar of revenue. On growth, REINSURANCE GROUP OF AMERICA INC posted the faster year-over-year revenue change (26.6% vs 4.7%). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs 2.3%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Reinsurance Group of America, Incorporated is a holding company for a global life and health reinsurance entity based in Greater St. Louis within the western suburb of Chesterfield, Missouri, United States. With approximately $3.9 trillion of life reinsurance in force and assets of $118.7 billion as of December 31, 2024, RGA has grown to become the only international company to focus primarily on life and health-related reinsurance.
GILD vs RGA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $6.6B |
| Net Profit | $2.2B | $463.0M |
| Gross Margin | 79.5% | — |
| Operating Margin | 25.0% | 7.7% |
| Net Margin | 27.5% | 7.0% |
| Revenue YoY | 4.7% | 26.6% |
| Net Profit YoY | 22.4% | 212.8% |
| EPS (diluted) | $1.75 | $6.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.9B | $6.6B | ||
| Q3 25 | $7.8B | $6.2B | ||
| Q2 25 | $7.1B | $5.6B | ||
| Q1 25 | $6.7B | $5.3B | ||
| Q4 24 | $7.6B | $5.2B | ||
| Q3 24 | $7.5B | $5.7B | ||
| Q2 24 | $7.0B | $4.9B | ||
| Q1 24 | $6.7B | $6.3B |
| Q4 25 | $2.2B | $463.0M | ||
| Q3 25 | $3.1B | $253.0M | ||
| Q2 25 | $2.0B | $180.0M | ||
| Q1 25 | $1.3B | $286.0M | ||
| Q4 24 | $1.8B | $148.0M | ||
| Q3 24 | $1.3B | $156.0M | ||
| Q2 24 | $1.6B | $203.0M | ||
| Q1 24 | $-4.2B | $210.0M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.8% | — |
| Q4 25 | 25.0% | 7.7% | ||
| Q3 25 | 42.8% | 5.2% | ||
| Q2 25 | 34.9% | 6.1% | ||
| Q1 25 | 33.6% | 7.0% | ||
| Q4 24 | 32.4% | 4.3% | ||
| Q3 24 | 11.8% | 3.8% | ||
| Q2 24 | 38.0% | 5.5% | ||
| Q1 24 | -64.6% | 4.3% |
| Q4 25 | 27.5% | 7.0% | ||
| Q3 25 | 39.3% | 4.1% | ||
| Q2 25 | 27.7% | 3.2% | ||
| Q1 25 | 19.7% | 5.4% | ||
| Q4 24 | 23.6% | 2.8% | ||
| Q3 24 | 16.6% | 2.8% | ||
| Q2 24 | 23.2% | 4.2% | ||
| Q1 24 | -62.4% | 3.3% |
| Q4 25 | $1.75 | $6.91 | ||
| Q3 25 | $2.43 | $3.81 | ||
| Q2 25 | $1.56 | $2.70 | ||
| Q1 25 | $1.04 | $4.27 | ||
| Q4 24 | $1.43 | $2.21 | ||
| Q3 24 | $1.00 | $2.33 | ||
| Q2 24 | $1.29 | $3.03 | ||
| Q1 24 | $-3.34 | $3.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $4.2B |
| Total DebtLower is stronger | $24.9B | $5.7B |
| Stockholders' EquityBook value | $22.7B | $13.5B |
| Total Assets | $59.0B | $156.6B |
| Debt / EquityLower = less leverage | 1.10× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.0M | $4.2B | ||
| Q3 25 | $19.0M | $4.6B | ||
| Q2 25 | $69.0M | $5.4B | ||
| Q1 25 | — | $5.2B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $4.6B | ||
| Q1 24 | — | $5.9B |
| Q4 25 | $24.9B | $5.7B | ||
| Q3 25 | $24.9B | $5.7B | ||
| Q2 25 | $24.9B | $5.7B | ||
| Q1 25 | $25.0B | $5.7B | ||
| Q4 24 | $26.7B | $5.0B | ||
| Q3 24 | $23.2B | $5.1B | ||
| Q2 24 | $23.3B | $5.1B | ||
| Q1 24 | $25.2B | $4.4B |
| Q4 25 | $22.7B | $13.5B | ||
| Q3 25 | $21.5B | $13.0B | ||
| Q2 25 | $19.7B | $12.1B | ||
| Q1 25 | $19.2B | $11.4B | ||
| Q4 24 | $19.3B | $10.8B | ||
| Q3 24 | $18.5B | $11.1B | ||
| Q2 24 | $18.3B | $9.7B | ||
| Q1 24 | $17.5B | $9.5B |
| Q4 25 | $59.0B | $156.6B | ||
| Q3 25 | $58.5B | $152.0B | ||
| Q2 25 | $55.7B | $133.5B | ||
| Q1 25 | $56.4B | $128.2B | ||
| Q4 24 | $59.0B | $118.7B | ||
| Q3 24 | $54.5B | $120.3B | ||
| Q2 24 | $53.6B | $109.9B | ||
| Q1 24 | $56.3B | $106.0B |
| Q4 25 | 1.10× | 0.42× | ||
| Q3 25 | 1.16× | 0.44× | ||
| Q2 25 | 1.27× | 0.48× | ||
| Q1 25 | 1.30× | 0.50× | ||
| Q4 24 | 1.38× | 0.47× | ||
| Q3 24 | 1.26× | 0.46× | ||
| Q2 24 | 1.28× | 0.52× | ||
| Q1 24 | 1.44× | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $7.3B |
| Free Cash FlowOCF − Capex | $3.1B | — |
| FCF MarginFCF / Revenue | 39.4% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 1.52× | 15.83× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $7.3B | ||
| Q3 25 | $4.1B | $-990.0M | ||
| Q2 25 | $827.0M | $-820.0M | ||
| Q1 25 | $1.8B | $-1.4B | ||
| Q4 24 | $3.0B | $17.1B | ||
| Q3 24 | $4.3B | $-1.1B | ||
| Q2 24 | $1.3B | $-967.0M | ||
| Q1 24 | $2.2B | $-5.7B |
| Q4 25 | $3.1B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $720.0M | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $2.8B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | 39.4% | — | ||
| Q3 25 | 51.0% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 24.8% | — | ||
| Q4 24 | 37.4% | — | ||
| Q3 24 | 55.2% | — | ||
| Q2 24 | 17.2% | — | ||
| Q1 24 | 31.6% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 1.52× | 15.83× | ||
| Q3 25 | 1.35× | -3.91× | ||
| Q2 25 | 0.42× | -4.56× | ||
| Q1 25 | 1.34× | -5.00× | ||
| Q4 24 | 1.67× | 115.81× | ||
| Q3 24 | 3.44× | -6.84× | ||
| Q2 24 | 0.82× | -4.76× | ||
| Q1 24 | — | -27.31× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
RGA
Segment breakdown not available.
